These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 29053717)
1. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent. Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Cheewatrakoolpong B; Xue J; Szeto D; Forrest G; Miller C; Bunzel M; Plummer CW; Chobanian HR; Miller MW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Li X; Feng Y; Tatosian DA; Howard AD; Colletti SL; Trujillo ME PLoS One; 2017; 12(10):e0186033. PubMed ID: 29053717 [TBL] [Abstract][Full Text] [Related]
2. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists. Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371 [TBL] [Abstract][Full Text] [Related]
3. GPR40 reduces food intake and body weight through GLP-1. Gorski JN; Pachanski MJ; Mane J; Plummer CW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Cheewatrakoolpong B; Howard AD; Colletti SL; Trujillo ME Am J Physiol Endocrinol Metab; 2017 Jul; 313(1):E37-E47. PubMed ID: 28292762 [TBL] [Abstract][Full Text] [Related]
4. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808 [TBL] [Abstract][Full Text] [Related]
5. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion. Tanaka H; Yoshida S; Minoura H; Negoro K; Shimaya A; Shimokawa T; Shibasaki M Life Sci; 2014 Jan; 94(2):115-21. PubMed ID: 24269216 [TBL] [Abstract][Full Text] [Related]
6. GPR40-Mediated G Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336 [TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170 [TBL] [Abstract][Full Text] [Related]
8. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity. Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471 [TBL] [Abstract][Full Text] [Related]
9. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve. Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244 [TBL] [Abstract][Full Text] [Related]
10. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats. Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664 [TBL] [Abstract][Full Text] [Related]
11. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production. Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610 [TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of Novel, Selective GPR40 AgoPAMs. Plummer CW; Clements MJ; Chen H; Rajagopalan M; Josien H; Hagmann WK; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Nolting AF; Orr R; Christensen M; Campeau LC; Wright MJ; Bugianesi R; Souza S; Zhang X; Di Salvo J; Weinglass AB; Tschirret-Guth R; Nargund R; Howard AD; Colletti SL ACS Med Chem Lett; 2017 Feb; 8(2):221-226. PubMed ID: 28197316 [TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold. Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660 [TBL] [Abstract][Full Text] [Related]
14. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat. Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448 [TBL] [Abstract][Full Text] [Related]
15. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278 [TBL] [Abstract][Full Text] [Related]
16. Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities. Jurica EA; Wu X; Williams KN; Haque LE; Rampulla RA; Mathur A; Zhou M; Cao G; Cai H; Wang T; Liu H; Xu C; Kunselman LK; Antrilli TM; Hicks MB; Sun Q; Dierks EA; Apedo A; Moore DB; Foster KA; Cvijic ME; Panemangalore R; Khandelwal P; Wilkes JJ; Zinker BA; Robertson DG; Janovitz EB; Galella M; Li YX; Li J; Ramar T; Jalagam PR; Jayaram R; Whaley JM; Barrish JC; Robl JA; Ewing WR; Ellsworth BA Bioorg Med Chem; 2023 May; 85():117273. PubMed ID: 37030194 [TBL] [Abstract][Full Text] [Related]
17. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. Luo J; Swaminath G; Brown SP; Zhang J; Guo Q; Chen M; Nguyen K; Tran T; Miao L; Dransfield PJ; Vimolratana M; Houze JB; Wong S; Toteva M; Shan B; Li F; Zhuang R; Lin DC PLoS One; 2012; 7(10):e46300. PubMed ID: 23056280 [TBL] [Abstract][Full Text] [Related]
18. The acute glucose lowering effect of specific GPR120 activation in mice is mainly driven by glucagon-like peptide 1. Sundström L; Myhre S; Sundqvist M; Ahnmark A; McCoull W; Raubo P; Groombridge SD; Polla M; Nyström AC; Kristensson L; Någård M; Winzell MS PLoS One; 2017; 12(12):e0189060. PubMed ID: 29206860 [TBL] [Abstract][Full Text] [Related]
19. Evaluating insulin secretagogues in a humanized mouse model with functional human islets. Luo J; Nguyen K; Chen M; Tran T; Hao J; Tian B; Rulifson IC; Zhang Y; Tian L; Zhang Y; Lopez E; Lin DC; Wang Y; Ma Z; Houze J; Guo Z Metabolism; 2013 Jan; 62(1):90-9. PubMed ID: 22982177 [TBL] [Abstract][Full Text] [Related]
20. Combined Deletion of Free Fatty-Acid Receptors 1 and 4 Minimally Impacts Glucose Homeostasis in Mice. Croze ML; Guillaume A; Ethier M; Fergusson G; Tremblay C; Campbell SA; Maachi H; Ghislain J; Poitout V Endocrinology; 2021 Mar; 162(3):. PubMed ID: 33543237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]